LevormeloxifeneAlternative Names: 6720 CDRI; Levomeloxifene; NNC 460020
Latest Information Update: 15 Jan 2003
At a glance
- Originator Central Drug Research Institute
- Developer Novo Nordisk; Novo Nordisk Pharma; Takeda
- Class Pyrrolidines
- Mechanism of Action Selective estrogen receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis